<DOC>
	<DOCNO>NCT02015663</DOCNO>
	<brief_summary>To provide efficacy safety data compare two dose schedule Tobramycin Inhalation Powder ( TIP ) treatment pulmonary Pseudomonas aeruginosa patient cystic fibrosis .</brief_summary>
	<brief_title>Tobramycin Inhalation Powder ( TIP ) Administered Once Daily Continuously Versus TIP Administered BID 28 Day / 28 Day Off Cycles</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>1 . Provide write informed consent , HIPPA ( Health Insurance Portability Accountability Act ) authorization ( applicable ) , assent ( appropriate ) prior performance studyrelated procedure . 2 . Confirmed diagnosis CF 3 . FEV1 screening ( Visit 1 ) ≥25 % ≤ 80 % normal predict value age , sex , height 4 . P. aeruginosa must present within 6 month prior screen screen 5 . Able comply protocol requirement 6 . Clinically stable opinion investigator 1 . History Burkholderia cenocepacia ( Bcc ) complex within 2 year prior screen and/or Bcc complex screen 2 . Hemoptysis 60 cc time within 30 day prior study drug administration 3 . History hearing loss chronic tinnitus deem clinically significant investigator 4 . Serum creatinine 2 mg/dL great , BUN 40 mg/dL great , abnormal urinalysis define 2+ great proteinuria screen 5 . Known local systemic hypersensitivity aminoglycosides inhale antibiotic 6 . Patients unable discontinue previously receive inhaled antibiotic regimen ( ) ( inhaled antibiotic allow study drug ) 7 . Use inhaled aminoglycosides within 28 day prior study drug administration ( Visit 2 ) 8 . Use systemic antipseudomonal antibiotic within 28 day prior study drug administration 9 . Use loop diuretic within 7 day prior study drug administration 10 . Administration investigational drug within 30 day prior enrollment 5 halflives , whichever longer 11 . Signs symptom acute pulmonary disease , e.g , pneumonia , pneumothorax 12 . Hospitalization baseline visit 13 . History malignancy 14 . Patients clinically significant laboratory abnormality ( associate study indication ) screen 15 . Patients clinically significant condition ( associate study indication ) might interfere assessment study 16 . Patients caregiver history noncompliance medical regimen patient caregiver consider potentially unreliable 17 . Pregnant nursing ( lactate ) woman 18 . Women childbearing potential , defined woman physiologically capable become pregnant , include woman whose career , lifestyle , sexual orientation precludes intercourse male partner woman whose partner sterilize vasectomy mean , UNLESS use two birth control method . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>CF</keyword>
</DOC>